Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single-center, multi-arm phase Ib study [0.03%]
校正内容：Selinexor联合卡铂和紫杉醇治疗晚期实体瘤患者：单中心、多组别Ⅰb期研究结果
Kyaw Z Thein,Daniel D Karp,Apostolia Tsimberidou et al.
Kyaw Z Thein et al.
Published Erratum
Investigational new drugs. 2025 Feb 20. DOI:10.1007/s10637-024-01493-5 2025
A phase I dose-escalation and expansion study of RMX1002, a selective E-type prostanoid receptor 4 antagonist, as monotherapy and in combination with anti-PD-1 antibody in advanced solid tumors [0.03%]
RMX1002，一种选择性的E型前列腺素受体4拮抗剂，作为单一疗法和与抗PD-1抗体组合在晚期实体瘤中的一期剂量递增和扩展研究
Dan Liu,Jifang Gong,Jian Zhang et al.
Dan Liu et al.
RMX1002 (grapiprant) is a selective E-type prostanoid receptor 4 (EP4) antagonist and a promising candidate for cancer therapy, potentially enhancing anti-tumor immune responses. This study aimed to evaluate the safety, pharmacokinetics, ph...
Helin Li,Xuelian Shen,Yu Chu et al.
Helin Li et al.
Research on prodrug technology has opened new avenues for site-directed chemotherapy rather than systemic chemotherapy. This distinctive strategy allows drug delivery to be activated by light-, irradiation-, or ultrasound (US)-tunable chemi...
Cardioprotective effects of PARP inhibitors for platinum-agent induced cardiotoxicity [0.03%]
PARP抑制剂对铂类药物诱导的心脏毒性的保护作用
Jae Hyun Kim,Ja-Young Han,Jae-Hee Kwon et al.
Jae Hyun Kim et al.
Poly(ADP-ribose) polymerase (PARP) inhibitors may have cardioprotective properties. This study aimed to evaluate the potential cardioprotective effects of PARP inhibitors in patients with epithelial ovarian cancer treated with platinum-base...
Progress of KRAS G12C inhibitors in the treatment of refractory colorectal cancer and strategies for drug resistance response [0.03%]
KRAS G12C抑制剂在治疗耐药结直肠癌中的进展及药物耐受性应对策略
Peiyuan Yang,Yongchao Li
Peiyuan Yang
Colorectal cancer is the third most prevalent cancer in the world. Early screening and detection of tumours, active surgical radical treatment, postoperative adjuvant chemotherapy, targeted therapy, and immunotherapy are performed based on ...
HDAC6 inhibition through WT161 synergizes with temozolomide, induces apoptosis, reduces cell motility, and decreases β-catenin levels in glioblastoma cells [0.03%]
通过WT161抑制HDAC6与替莫唑胺协同作用，诱导胶质母细胞瘤细胞凋亡，降低细胞运动能力和β-连环蛋白水平
Leilane Sales Oliveira,João Marcos Oliveira-Silva,Hebreia Oliveira Almeida-Souza et al.
Leilane Sales Oliveira et al.
Glioblastoma multiforme (GBM) accounts for 70% of all primary malignancies of the central nervous system. Current treatment strategies involve surgery followed by chemotherapy with temozolomide (TMZ); however, the median survival after trea...
Efficacy and safety of fruquintinib plus capecitabine as first-line treatment in patients with metastatic colorectal cancer ineligible for intravenous chemotherapy: a two-stage, single-armed, phase II study [0.03%]
弗鲁喹替尼联合卡培他滨用于不适合静脉化疗的转移性结直肠癌一线治疗的疗效及安全性：一项两阶段单臂II期临床试验
Xin Wang,Zhigang Bai,Wei Deng et al.
Xin Wang et al.
Fruquintinib has been recommended for treating refractory metastatic colorectal cancer. This single-arm, phase II study explored for the first time whether fruquintinib combined with capecitabine could be used as a first-line treatment for ...
DYNC2H1 mutation as a potential predictive biomarker for immune checkpoint inhibitor efficacy in NSCLC and melanoma [0.03%]
DYNC2H1突变可能是免疫检查点抑制剂治疗非小细胞肺癌和黑色素瘤疗效的预测性生物标志物
Lu Yang,Yanlong Feng,Xuewen Liu et al.
Lu Yang et al.
Dynein cytoplasmic 2 heavy chain 1 (DYNC2H1) is reported to play a potential role in cancer immunotherapy. However, the association between DYNC2H1 mutation and the clinical benefit of immunotherapy in non-small cell lung cancer (NSCLC) and...
Clinical features, diagnosis, and treatment of pembrolizumab induced autoimmune encephalitis [0.03%]
派姆单抗诱导的自身免疫性脑炎的临床特点、诊断及治疗
Li Zou,Xianlin Rao,Xiyue Zhao
Li Zou
Pembrolizumab has shown links to autoimmune encephalitis (AE), yet the exact clinical characteristics remain unclear. This study examines the clinical features of pembrolizumab-induced AE to enhance diagnostic accuracy and therapeutic strat...
Targeting MYC for the treatment of breast cancer: use of the novel MYC-GSPT1 degrader, GT19630 [0.03%]
靶向MYC治疗乳腺癌：新型MYC-GSPT1降解剂GT19630的应用
Minhong Tang,John Crown,Michael J Duffy
Minhong Tang
Background: Since MYC is one of the most frequently altered driver genes involved in cancer formation, it is a potential target for new anti-cancer therapies. Historically, however, MYC has proved difficult to target due ...